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Pituitary adenomas are common benign monoclonal 
neoplasms accounting for approximately 15% of 
intracranial tumors, while occult adenomas are 
discovered in as many as 25% of unselected autopsies. 
Pituitary tumors are usually benign, but cause 
significant morbidity due to their critical location, 
expanding size, and/or inappropriate pituitary hormne 
expression. True malignant behaviour with metastatic 
spread is very rare. 
Classification 
 
The relative incidence of the different pituitary adenomas 
subtypes is diagrammed in Fig.1 
Various subtypes have been recognized on the basis of 
clinical presentation, as well as immunocytological and 
ultrastructural characteristics. About one-third of  
 
 
pituitary adenomas are not associated with clinical  
hypersecretory syndromes, but with symptoms of an 
intracranial mass such as headaches, hypopituitarism, 
or visual field disturbances, and are classified as 
nonfunctioning pituitary adenomas (NFPAs). Clinically 
non-functioning adenomas (NFPA) are actually a 
diverse group of tumors that include LH-, FSH- 
secreting adenomas, null cell adenoma and 
oncocytoma. The clinical features of all other pituitary 
adenomas are linked to the hypersecreted hormone(s) 
which mark the specific cell origin, allowing the 
tumors to be classified as: 
Prolactinomas or PRL-secreting PA, the most common 
of all functional pituitary adenomas. The patients 
usually present with amenorrhea, infertility, and 
galactorrhea (females), impotence or infertility (males). 
Tumors expressing both PRL and GH are thought to 
originate from a common mammosomatotroph 
precursor cell. 
Somatotropinomas or GH-secreting PA, which cause 
acromegaly in adults, with bony acral changes in soft 
tissues and bone, and increased risk of hypertension, 
cardiac disease, and diabetes. 
Corticotropinomas or ACTH-secreting PA, leading to 
Cushing disease and adrenal steroid overstimulation. 
Features of hypercortisolism include truncal obesity, 
striae, muscle wasting, hirsutism, cardiovascular 
complications, osteoporosis, and psychiatric 
disturbances. 
Pure gonadotropinomas secreting intact FSH or LH are 
rarely encountered and may cause sexual dysfunction 
and hypogonadism. 
Thyrotropinomas cause a mild increase in thyroxine 
levels with inappropriate TSH levels. 
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Clinics and pathology 
Treatment 
PRL: medical therapy to reduce prolactin secretion and
tumor size by using dopamine agonists such as 
bromocriptine, cabergoline and quinagolide. Trans-
sphenoidal surgery may be required for drug resistant 
tumours or drug-intolerant individuals. 
NFPA: in the presence of clinical signs, the primary 
treatment is trans-sphenoidal surgery. Medical and 
radiation therapy are considered following incomplete 
tumor resection. Patients without clinical signs are 
followed-up by MRI scans and visual field checks. 
GH: treatment depends on the adenoma size/activity 
and patient's age. Trans-sphenoidal surgery is the 
treatment of choice in most cases and can be 
dramatically effective, especially for microadenomas. 
Following surgery some patients may need 
radiotherapy and medical treatment with bromocriptine 
or somatostatin analogues to reduce prolactin secretion 
or inhibiting GH release from the pituitary. 
ACTH: the usual treatment is trans-sphenoidal surgery 
which leads to rapid disappearance of cortisol from the 
blood. When surgery is unsuccessful, radiotherapy is 
administered. Drugs such as metyrapone, ketoconazole 
and o,p'DDD are used to control cortisol levels, 
particularly before surgery. 
Evolution 
Is dependent on adenoma subtype. A significantly 
higher frequency of multiple allelic deletions were 
found in invasive tumors compared to non-invasive 
tumors. 
Prognosis 
Usually favourable. Truly malignant metastatic 
behaviour is extremely rare. The unresponsiveness to 




Little is known about the genetic defects leading to 
pituitary tumor formation, which likely involves 
multiple initiating and promoting factors. 
With the exception of activating mutations of GNAS1 
which have been associated with 40% of somatotrophic 
adenomas and 10% of NFPAs, none of the candidate 
cell cycle, receptor, second messenger or related genes 
examined thus far appears to be responsible 
individually for more than a few percent of sporadic 
pituitary adenomas. 
Inactivation of p27kip1 and RB1 has been associated 
with the development of pituitary adenomas in mice, 
but no similar evidence has been achieved in human. 
MEN1A mutations, commonly found in patients  
affected by the MEN-1 syndrome, are rarely found in 
sporadic pituitary adenomas, despite a menin variably 
diminished expression has been demonstrated. 
Increased expression of pituitary tumor transforming 
gene (PTTG) has been found in sporadic pituitary 
adenomas, and a role for this gene in pituitary cell
proliferation is supported by development of multifocal 
plurihormonal focal pituitary adenomas in transgenic 
male mice overexpressing PTTG. 
A role for HMGA2 gene in pituitary oncogenesis has 
been pointed out by development of PRL adenomas in 
HMGA2 transgenic mice and the finding of HMGA2 
expression, which is switched off in the adult pituitary 
gland, in human prolactinomas. Amplification and/or 
rearrangement of the HMGA2 gene, mapping to 12q14, 
was observed in most of the PRLs analyzed. Increased 
dosage of chromosome 12 appears to be a condition 
predisposing to selective overrepresentation of the
12q14 region and/or rearrangement of the HMGA2 
gene. 
Expression of HMGA2 has been recorded also in 
human NFPA, which rarely harbor trisomy 12, 
suggesting a mechanism of activation different from 
that mainly operating in PRLs (Figure 2). 
It remains to be determined which of the many 
oncogenes/growth factors and oncosuppressors 
reported overexpressed or underexpressed contribute to 
pituitary oncogenesis to identify the pathogenetic 
pathways which are altered in pituitary adenomas. 
Cytogenetics 
Note 
Cytogenetic analysis failed for some time to identify 
recurrent chromosomal anomalies which might 
correlate with a clinical adenoma subtype or with a 
defined tumor stage. 
Technical difficulties related to the size of the samples 
available after surgery and the low proliferative rate of 
pituitary cells account for the limited cytogenetic 
findings. Despite these constraints a small fraction of 
pituitary adenomas showed an abnormal karyotype 
characterized by hyperdiploid or near triploid modal 
chromosome numbers and rare random structural 
abnormalities. Microsatellite and interphase FISH 
studies indicated that trisomy of chromosome 12 is 
pathogenetically important, and represents the most 
frequent cytogenetic alteration in human PRL. 
Chromosomes 5, 8 and X were also found to be 
preferentially overrepresented (Figure 3). Combined 
gains of the above chromosomes appear a non random 
pattern in pituitary adenoma. Comparative genomic 
hybridization (CGH) studies confirmed the cytogenetic 
and FISH evidence, but did not provide significant 
clues to specific subchromosomal regions. 










Figure 2. Interphase and metaphase FISH of HMGA2 dosage in human pituitary adenomas. Dual-color FISH of 669g18 +698i6 
BACs(targeting the entire HMGA2 genomic region, red) and pBR12 (alphoid-specific probe of chromosome 12,D12Z3locus, green) 
showing: (a) disomy of both regions in a NFPA tumor expressing HMGA2 and (b) increased number of signals given by HMGA2-specific 
BACs as compared to that given by the alphoid probe on a NFPA expressing HMGA2. Note one HMGA2 signal on a marker 
chromosome (arrowed).Figure 3. Interphase dual-color FISH of probes pBR12 (D12Z3 locus, green fluorescence) and pDMX1 (DXZ1 
locus, red) showing trisomic and disomic dosage of chromosomes 12 and X respectively, in a PRL pituitary adenoma. 
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